Gene Patent Case Has The Industry’s Attention

A loss for Myriad Genetics in a matter now before the Supreme Court could be a big setback for the biotech industry and invalidate thousands of existing patents, according to one IP practitioner. Public interest groups that are represented in the case, Association for Molecular Pathology v. Myriad Genetics, say that gene patents block progress in personalized medicine and are fundamentally wrong.